Sepsis — Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study
Citation(s)
Aneja R, Carcillo JA What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock? Arch Dis Child. 2007 Feb;92(2):165-9. Epub 2006 Sep 26. Review.
Bellomo R, McGrath B, Boyce N Effect of continuous venovenous hemofiltration with dialysis on hormone and catecholamine clearance in critically ill patients with acute renal failure. Crit Care Med. 1994 May;22(5):833-7.
Derkx B, Wittes J, McCloskey R Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis. 1999 Apr;28(4):770-7.
Faust SN, Heyderman RS, Levin M Disseminated intravascular coagulation and purpura fulminans secondary to infection. Baillieres Best Pract Res Clin Haematol. 2000 Jun;13(2):179-97. Review.
Fessler MB, O'Brien JM, Douglas IS Laboratory predictors of relative adrenal insufficiency in septic shock. Crit Care Med. 2003 Aug;31(8):2251-2; author reply 2252-3.
Heyderman RS, Ison CA, Peakman M, Levin M, Klein NJ Neutrophil response to Neisseria meningitidis: inhibition of adhesion molecule expression and phagocytosis by recombinant bactericidal/permeability-increasing protein (rBPI21). J Infect Dis. 1999 May;179(5):1288-92.
Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet. 1999 Mar 27;353(9158):1049-53.
Hildebrandt T, Mansour M, Al Samsam R The use of steroids in children with septicemia: review of the literature and assessment of current practice in PICUs in the UK. Paediatr Anaesth. 2005 May;15(5):358-65. Review.
Johnston JA, Yi MS, Britto MT, Mrus JM Importance of organ dysfunction in determining hospital outcomes in children. J Pediatr. 2004 May;144(5):595-601.
Keh D, Sprung CL Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med. 2004 Nov;32(11 Suppl):S527-33. Review.
Kirschbaum C, Hellhammer DH Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology. 1994;19(4):313-33. Review.
Luscombe M, Owens B Weight estimation in resuscitation: is the current formula still valid? Arch Dis Child. 2007 May;92(5):412-5. Epub 2007 Jan 9. Erratum in: Arch Dis Child. 2007 Jul;92(7):657.
Marik PE, Zaloga GP Adrenal insufficiency during septic shock. Crit Care Med. 2003 Jan;31(1):141-5.
Marik PE, Zaloga GP Adrenal insufficiency in the critically ill: a new look at an old problem. Chest. 2002 Nov;122(5):1784-96. Review.
Maxime V, Fitting C, Annane D, Cavaillon JM Corticoids normalize leukocyte production of macrophage migration inhibitory factor in septic shock. J Infect Dis. 2005 Jan 1;191(1):138-44. Epub 2004 Nov 30.
Nadel S, Newport MJ, Booy R, Levin M Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996 Oct;174(4):878-80.
Stoll BJ, Holman RC, Schuchat A Decline in sepsis-associated neonatal and infant deaths in the United States, 1979 through 1994. Pediatrics. 1998 Aug;102(2):e18.
Weale NK, Rogers CA, Cooper R, Nolan J, Wolf AR Effect of remifentanil infusion rate on stress response to the pre-bypass phase of paediatric cardiac surgery. Br J Anaesth. 2004 Feb;92(2):187-94.
Wetherell MA, Crown AL, Lightman SL, Miles JN, Kaye J, Vedhara K The four-dimensional stress test: psychological, sympathetic-adrenal-medullary, parasympathetic and hypothalamic-pituitary-adrenal responses following inhalation of 35% CO2. Psychoneuroendocrinology. 2006 Jul;31(6):736-47. Epub 2006 Apr 18.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.